FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2172492020> ?p ?o ?g. }

• W2172492020 endingPage "2495" @default.
• W2172492020 startingPage "2495" @default.
• W2172492020 abstract "Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis Afisi Segun Ismaila,1,2 Eline L Huisman,3 Yogesh Suresh Punekar,4 Andreas Karabis31Value Evidence and Outcomes, GlaxoSmithKline, Research Triangle Park, NC, USA; 2Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada; 3Real World Strategy and Analytics, Mapi Group, Houten, the Netherlands; 4Value Evidence and Outcomes, GlaxoSmithKline, Uxbridge, UKBackground: Randomized, controlled trials comparing long-acting muscarinic antagonist (LAMA) efficacy in COPD are limited. This network meta-analysis (NMA) assessed the relative efficacy of tiotropium 18 µg once-daily (OD) and newer agents (aclidinium 400 µg twice-daily, glycopyrronium 50 µg OD, and umeclidinium 62.5 µg OD).Methods: A systematic literature review identified randomized, controlled trials of adult COPD patients receiving LAMAs. A NMA within a Bayesian framework examined change from baseline in trough forced expiratory volume in 1 second (FEV1), transitional dyspnea index focal score, St George’s Respiratory Questionnaire score, and rescue medication use.Results: Twenty-four studies (n=21,311) compared LAMAs with placebo/each other. Aclidinium, glycopyrronium, tiotropium, and umeclidinium, respectively, demonstrated favorable results versus placebo, for change from baseline (95% credible interval) in 12-week trough FEV1 (primary endpoint: 101.40 mL [77.06–125.60]; 117.20 mL [104.50–129.90]; 114.10 mL [103.10–125.20]; 136.70 mL [104.20–169.20]); 24-week trough FEV1 (128.10 mL [84.10–172.00]; 135.80 mL [123.10–148.30]; 106.40 mL [95.45–117.30]; 115.00 mL [74.51–155.30]); 24-week St George’s Respiratory Questionnaire score (-4.60 [-6.76 to -2.54]; -3.14 [-3.83 to -2.45]; -2.43 [-2.92 to -1.93]; -4.69 [-7.05 to -2.31]); 24-week transitional dyspnea index score (1.00 [0.41–1.59]; 1.01 [0.79–1.22]; 0.82 [0.62–1.02]; 1.00 [0.49–1.51]); and 24-week rescue medication use (data not available; -0.41 puffs/day [-0.62 to -0.20]; -0.52 puffs/day [-0.74 to -0.30]; -0.30 puffs/day [-0.81 to 0.21]). For 12-week trough FEV1, differences in change from baseline (95% credible interval) were -12.8 mL (-39.39 to 13.93), aclidinium versus tiotropium; 3.08 mL (-7.58 to 13.69), glycopyrronium versus tiotropium; 22.58 mL (-11.58 to 56.97), umeclidinium versus tiotropium; 15.90 mL (-11.60 to 43.15), glycopyrronium versus aclidinium; 35.40 mL (-5.06 to 76.07), umeclidinium versus aclidinium; and 19.50 mL (-15.30 to 54.38), umeclidinium versus glycopyrronium. Limitations included inhaler-related factors and safety; longer-term outcomes were not considered.Conclusion: The new LAMAs studied had at least comparable efficacy to tiotropium, the established class standard. Choice should depend on physician’s and patient’s preference.Keywords: anticholinergics, muscarinic antagonist, bronchodilator, systematic review, meta-analysis" @default.
• W2172492020 created "2016-06-24" @default.
• W2172492020 creator A5001789783 @default.
• W2172492020 creator A5030471784 @default.
• W2172492020 creator A5067179752 @default.
• W2172492020 creator A5067651492 @default.
• W2172492020 date "2015-11-01" @default.
• W2172492020 modified "2023-10-16" @default.
• W2172492020 title "Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis" @default.
• W2172492020 cites W1704063072 @default.
• W2172492020 cites W1954671479 @default.
• W2172492020 cites W1966561347 @default.
• W2172492020 cites W1969836944 @default.
• W2172492020 cites W1971649226 @default.
• W2172492020 cites W1980789906 @default.
• W2172492020 cites W1981197711 @default.
• W2172492020 cites W2005640821 @default.
• W2172492020 cites W2011096338 @default.
• W2172492020 cites W2017287154 @default.
• W2172492020 cites W2029276834 @default.
• W2172492020 cites W2035613798 @default.
• W2172492020 cites W2037965009 @default.
• W2172492020 cites W2039237831 @default.
• W2172492020 cites W2044624199 @default.
• W2172492020 cites W2051449385 @default.
• W2172492020 cites W2070935883 @default.
• W2172492020 cites W2079404821 @default.
• W2172492020 cites W2100215089 @default.
• W2172492020 cites W2105402505 @default.
• W2172492020 cites W2112433656 @default.
• W2172492020 cites W2113026917 @default.
• W2172492020 cites W2123850585 @default.
• W2172492020 cites W2125779455 @default.
• W2172492020 cites W2127622911 @default.
• W2172492020 cites W2129821518 @default.
• W2172492020 cites W2129929576 @default.
• W2172492020 cites W2134091333 @default.
• W2172492020 cites W2141034778 @default.
• W2172492020 cites W2142430815 @default.
• W2172492020 cites W2142449488 @default.
• W2172492020 cites W2144625636 @default.
• W2172492020 cites W2144805491 @default.
• W2172492020 cites W2149199480 @default.
• W2172492020 cites W2149827575 @default.
• W2172492020 cites W2160263482 @default.
• W2172492020 cites W2169957722 @default.
• W2172492020 cites W2171280425 @default.
• W2172492020 cites W2171697174 @default.
• W2172492020 cites W2171974515 @default.
• W2172492020 cites W4239080780 @default.
• W2172492020 doi "https://doi.org/10.2147/copd.s92412" @default.
• W2172492020 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4655912" @default.
• W2172492020 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26604738" @default.
• W2172492020 hasPublicationYear "2015" @default.
• W2172492020 type Work @default.
• W2172492020 sameAs 2172492020 @default.
• W2172492020 citedByCount "29" @default.
• W2172492020 countsByYear W21724920202015 @default.
• W2172492020 countsByYear W21724920202016 @default.
• W2172492020 countsByYear W21724920202017 @default.
• W2172492020 countsByYear W21724920202018 @default.
• W2172492020 countsByYear W21724920202019 @default.
• W2172492020 countsByYear W21724920202020 @default.
• W2172492020 countsByYear W21724920202021 @default.
• W2172492020 countsByYear W21724920202022 @default.
• W2172492020 crossrefType "journal-article" @default.
• W2172492020 hasAuthorship W2172492020A5001789783 @default.
• W2172492020 hasAuthorship W2172492020A5030471784 @default.
• W2172492020 hasAuthorship W2172492020A5067179752 @default.
• W2172492020 hasAuthorship W2172492020A5067651492 @default.
• W2172492020 hasBestOaLocation W21724920201 @default.
• W2172492020 hasConcept C126322002 @default.
• W2172492020 hasConcept C142724271 @default.
• W2172492020 hasConcept C168563851 @default.
• W2172492020 hasConcept C170493617 @default.
• W2172492020 hasConcept C1862650 @default.
• W2172492020 hasConcept C204787440 @default.
• W2172492020 hasConcept C27081682 @default.
• W2172492020 hasConcept C2776723954 @default.
• W2172492020 hasConcept C2776780178 @default.
• W2172492020 hasConcept C2776968687 @default.
• W2172492020 hasConcept C2777714996 @default.
• W2172492020 hasConcept C2780911369 @default.
• W2172492020 hasConcept C3018587741 @default.
• W2172492020 hasConcept C33789571 @default.
• W2172492020 hasConcept C71924100 @default.
• W2172492020 hasConceptScore W2172492020C126322002 @default.
• W2172492020 hasConceptScore W2172492020C142724271 @default.
• W2172492020 hasConceptScore W2172492020C168563851 @default.
• W2172492020 hasConceptScore W2172492020C170493617 @default.
• W2172492020 hasConceptScore W2172492020C1862650 @default.
• W2172492020 hasConceptScore W2172492020C204787440 @default.
• W2172492020 hasConceptScore W2172492020C27081682 @default.
• W2172492020 hasConceptScore W2172492020C2776723954 @default.
• W2172492020 hasConceptScore W2172492020C2776780178 @default.
• W2172492020 hasConceptScore W2172492020C2776968687 @default.
• W2172492020 hasConceptScore W2172492020C2777714996 @default.
• W2172492020 hasConceptScore W2172492020C2780911369 @default.

• next